GD 4040

Drug Profile

GD 4040

Alternative Names: V 21

Latest Information Update: 30 Aug 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inflazyme Pharmaceuticals; LEO Pharma
  • Class Anticoagulants; Antithrombotics; Glycosaminoglycans
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 27 Jul 2004 Discontinued - Preclinical for Thrombosis in USA (unspecified route)
  • 02 Mar 2004 No development reported - Preclinical for Thrombosis in USA (unspecified route)
  • 17 Jun 2003 GLYCODesign has been acquired by Inflazyme Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top